All In Biotech

Drug Trial Radar · NCT04732871

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,720 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,720

Actual

Start

Feb 15, 2021

Primary completion

Jun 6, 2022

Study completion Feb 19, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1Time frame: At Day 1
  2. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31Time frame: At Day 31
  3. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6Time frame: At Month 6
  4. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12Time frame: At Month 12
  5. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1Time frame: At Day 1
  6. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31Time frame: At Day 31
  7. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6Time frame: At Month 6
  8. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12Time frame: At Month 12

Locations

46 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    The Villages, Florida

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Richfield, Minnesota

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Mt. Pleasant, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Norfolk, Virginia

  • GSK Investigational Site

    Wenatchee, Washington

  • GSK Investigational Site

    Espoo, Finland

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Jarvenpaa, Finland

  • GSK Investigational Site

    Kokkola, Finland

  • GSK Investigational Site

    Oulu, Finland

  • GSK Investigational Site

    Seinäjoki, Finland

  • GSK Investigational Site

    Tampere, Finland

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Pori, Satakunta, Finland

  • GSK Investigational Site

    Essen, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Mainz, Germany

  • GSK Investigational Site

    München, Germany

  • GSK Investigational Site

    Wallerfing, Germany

  • GSK Investigational Site

    Würzburg, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Goch, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Kumamoto, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Changhua, Taiwan

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.